No connection

Search Results

GILD vs UNH

GILD
Gilead Sciences, Inc.
NEUTRAL
Price
$132.90
Market Cap
$164.96B
Sector
Healthcare
AI Confidence
85%
UNH
UnitedHealth Group Incorporated
NEUTRAL
Price
$323.48
Market Cap
$293.61B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
GILD
19.6
UNH
24.43
Forward P/E
GILD
13.81
UNH
16.08
P/B Ratio
GILD
7.27
UNH
3.11
P/S Ratio
GILD
5.6
UNH
0.66
EV/EBITDA
GILD
12.4
UNH
16.47

Profitability

Gross Margin
GILD
78.84%
UNH
18.53%
Operating Margin
GILD
37.38%
UNH
0.34%
Profit Margin
GILD
28.9%
UNH
2.69%
ROE
GILD
40.66%
UNH
12.54%
ROA
GILD
12.52%
UNH
3.9%

Growth

Revenue Growth
GILD
4.7%
UNH
12.3%
Earnings Growth
GILD
23.4%
UNH
-99.9%

Financial Health

Debt/Equity
GILD
1.13
UNH
0.82
Current Ratio
GILD
1.55
UNH
0.79
Quick Ratio
GILD
1.23
UNH
0.7

Dividends

Dividend Yield
GILD
2.47%
UNH
2.73%
Payout Ratio
GILD
46.61%
UNH
65.99%

AI Verdict

GILD NEUTRAL

GILD presents a stable financial profile with a Piotroski F-Score of 4/9 and a valuation that sits between a conservative Graham Number ($52.83) and a growth-based Intrinsic Value ($200.01). The company exhibits exceptional profitability with an ROE of 40.66% and a very attractive PEG ratio of 0.38, suggesting significant undervaluation relative to earnings growth. However, bearish technicals (0/100) and consistent insider selling by the CEO and CFO create significant short-term headwinds. While fundamentals are robust, the lack of price momentum and insider sentiment temper a bullish outlook.

Strengths
Exceptional profitability with 78.84% gross margins and 40.66% ROE
Highly attractive PEG ratio of 0.38 indicating undervaluation relative to growth
Strong earnings growth (YoY 23.40%) and consistent history of beating estimates
Risks
Bearish insider sentiment with selling from the CEO and CFO
Weak technical trend (0/100) indicating strong downward or stagnant momentum
Modest revenue growth (4.70%) compared to high earnings growth
UNH NEUTRAL

UnitedHealth Group presents a conflicted profile with a stable but mediocre Piotroski F-Score of 4/9 and a significant disconnect between current price ($323.48) and defensive fair value (Graham Number: $175.91). While revenue growth remains robust at 12.3%, the company has suffered a catastrophic collapse in YoY earnings growth (-99.9%), suggesting severe short-term headwinds or one-time accounting shocks. Technical trends are currently bearish (0/100), though a recent one-month bounce and a favorable Forward P/E of 16.08 indicate analyst expectations of a recovery. The stock is currently trading at a significant premium to its intrinsic value, relying heavily on its market dominance and future earnings normalization.

Strengths
Strong consistent revenue growth (12.3% YoY)
Manageable Debt/Equity ratio of 0.82
Attractive Forward P/E (16.08) compared to current P/E (24.43)
Risks
Extreme earnings volatility (YoY Earnings Growth -99.9%)
Poor liquidity indicated by a Current Ratio of 0.79
Extremely thin operating margins (0.34%)

Compare Another Pair

GILD vs UNH: Head-to-Head Comparison

This page compares Gilead Sciences, Inc. (GILD) and UnitedHealth Group Incorporated (UNH) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile